+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuromodulation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 141 Pages
  • September 2023
  • Region: Global
  • IMARC Group
  • ID: 5633190

Quick Summary:

In the evolving field of healthcare, the demand for effective and comprehensive methods of dealing with neurodegenerative diseases has never been higher. This is where the value of the latest neuromodulation market report becomes evident. Neuromodulation, a state-of-the-art technique involving the modulation of nerve activity via targeted delivery of electrical or pharmaceutical agents, offers ground-breaking applications in treating depression, Parkinson's disease, migraines and other ailments.

A key reason to invest in this report is the discernible market trends it highlights. Encouraging factors such as the rising geriatric population and an increase in neurodegenerative conditions globally promise sustained growth in the neuromodulation arena. Furthermore, the interplay of technological advancements such as lithium-ion batteries with high-density energy and the broadening utilization of techniques such as spinal cord stimulation and deep brain stimulation bolsters market dynamics. In addition, the report's insightful segmentation by technology, biomaterial and application affords a comprehensive understanding of the opportunities lying in this burgeoning sector. Coupled with a competitive analysis of major industry players, this report offers an invaluable resource for critical decision making and strategic planning for future business growth in the international neuromodulation market.

The global neuromodulation market size reached US$ 6.7 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 12.5 Billion by 2028, exhibiting a growth rate (CAGR) of 10.4% during 2023-2028.

Neuromodulation is a medical technique used for the modulation and alteration of nerve activities by delivering electrical or pharmaceutical agents directly to the targeted area. It consists of tiny electrodes that generate electrical stimulation with the help of pulse generators to supplement neurological activities in the patients. The electrodes are generally placed in the nerves, brain, or spinal cord, whereas pulse generators are implanted within the skin. Neuromodulation is widely used to treat depression, chronic pain, epilepsy, tremor, migraine, failed back syndrome, Parkinson's disease, and gastroparesis. It includes the vagal nerve, deep brain, transcranial magnetic, and electrical stimulation. It assists in monitoring nerve activity, alleviating symptoms, and normalizing activity levels in the brain.

Neuromodulation Market Trends:

The rising geriatric population and the increasing prevalence of Alzheimer's and Parkinson's diseases across the globe are key factors driving the market growth. Neuromodulation is widely used to treat overactive bladder, low movement, rigidity, tremor, walking problems, neurodegenerative, and neurological disorders. Moreover, technological innovations, such as the introduction of lithium-ion (Li-ion) batteries that provide high energy density, rechargeability, and enhanced cycling temperature, are providing a considerable boost to the market growth. Additionally, the widespread utilization of spinal cord stimulation (SCS) in various medical problems, such as complex regional pain syndrome, neuropathy, nerve damage, failed-back surgery syndrome, and arachnoiditis, is positively impacting the market growth. Apart from this, the increasing usage of deep brain stimulation (DBS) that delivers low bipolar or monopolar electric impulses and is used in the treatment of depression and obsessive-compulsive disorders (OCD) is creating a positive outlook for the market. Other factors, such as extensive research and development (R&D) activities and significant growth in the healthcare industry, are anticipated to drive the market toward growth.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global neuromodulation market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on technology, biomaterial and application.

Breakup by Technology:

  • Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
  • External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others

Breakup by Biomaterial:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

Breakup by Application:

  • Parkinson's Disease
  • Epilepsy
  • Depression
  • Dystonia
  • Pain Management
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp.

Key Questions Answered in This Report:

  • How has the global neuromodulation market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neuromodulation market?
  • What are the key regional markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the biomaterial?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neuromodulation market and who are the key players?
  • What is the degree of competition in the industry?
Frequently Asked Questions about the Global Neuromodulation Market

What is the estimated value of the Global Neuromodulation Market?

The Global Neuromodulation Market was estimated to be valued at $6.7 Billion in 2022.

What is the growth rate of the Global Neuromodulation Market?

The growth rate of the Global Neuromodulation Market is 11.0%, with an estimated value of $12.5 Billion by 2028.

What is the forecasted size of the Global Neuromodulation Market?

The Global Neuromodulation Market is estimated to be worth $12.5 Billion by 2028.

Who are the key companies in the Global Neuromodulation Market?

Key companies in the Global Neuromodulation Market include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics and NeuroPace Inc..

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Neuromodulation Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Internal Neuromodulation
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Spinal Cord Stimulation (SCS)
6.1.2.2 Deep Brain Stimulation (DBS)
6.1.2.3 Vagus Nerve Stimulation (VNS)
6.1.2.4 Sacral Nerve Stimulation (SNS)
6.1.2.5 Gastric Electrical Stimulation (GES)
6.1.3 Market Forecast
6.2 External Neuromodulation
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
6.2.2.2 Transcranial Magnetic Stimulation (TMS)
6.2.2.3 Others
6.2.3 Market Forecast
7 Market Breakup by Biomaterial
7.1 Metallic Biomaterials
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Polymeric Biomaterials
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Ceramic Biomaterials
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Parkinson's Disease
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Epilepsy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Depression
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Dystonia
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Pain Management
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bioventus Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Boston Scientific Corporation
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Helius Medical Technologies
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Integer Holdings Corporation
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 LivaNova PLC
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Medtronic plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 MicroTransponder Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Neuronetics
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 NeuroPace Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.11 NeuroSigma Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.12 Nevro Corp.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials

Companies Mentioned

  • Abbott Laboratories
  • Bioventus Inc.
  • Boston Scientific Corporation
  • Helius Medical Technologies
  • Integer Holdings Corporation
  • LivaNova PLC
  • Medtronic plc
  • MicroTransponder Inc.
  • Neuronetics
  • NeuroPace Inc.
  • NeuroSigma Inc.
  • Nevro Corp.

Methodology

Loading
LOADING...